{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a
to a specific field?
Status:
Investigational
Source:
NCT03770988: Phase 2 Interventional Unknown status Inoperable or Recurrent or Metastatic Esophageal Squamous Carcinoma
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Poziotinib is an inhibitor of EGFR tyrosine kinase family. The drug is being tested in phase II of clinical trials for different cancers: breast cancer, lung adenocarcinoma, head and neck squamous cell carcinoma, HER-2 positive advanced gastric cancer (in combination with Paclitaxel and Trastuzumab).
Status:
Investigational
Source:
NCT02048488: Phase 1/Phase 2 Interventional Completed Solid Tumors
(2012)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Belizatinib, also known as TSR-011, is an orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. Upon administration, ALK/TRK inhibitor TSR-011 binds to and inhibits both ALK and TRK kinases. The inhibition leads to disruption of ALK- and TRK-mediated signaling and impedes tumor cell growth in ALK/TRK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors.
Status:
Investigational
Source:
INN:enavogliflozin [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03412292: Phase 1 Interventional Unknown status Acute Myelogenous Leukemia (AML)
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01280344: Phase 2 Interventional Completed Gastrointestinal Dysmotility
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ipamorelin is a new and potent synthetic pentapeptide which has distinct and specific growth hormone (GH)-releasing properties. Ipamorelin mimics ghrelin and binds to the ghrelin receptor (or GH secretagogue receptor, GHSR) in the brain, thereby selectively stimulating the release of GH from the pituitary gland. This results in increased plasma GH levels, which would affect many biological processes. Besides its presence in the brain, GHSR can also be found in the gastrointestinal tract, heart, lung, liver, kidney, pancreas, adipose tissue and immune cells. Unlike other GH releasing peptides, ipamorelin only stimulates GH release in a manner very similar to that of growth hormone releasing hormone.
Status:
Investigational
Source:
NCT04362644: Phase 1 Interventional Recruiting Idiopathic Pulmonary Fibrosis
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
BAY85-8102 (widely known as (18)F-DPA-714) is a specific radioligand for the translocator protein (TSPO). TSPO, formerly known as the peripheral benzodiazepine receptor, is dramatically upregulated under pathologic conditions. BAY85-8102 in combination with positron emission tomography imaging participated in phase I clinical trials for investigation of neuroinflammation in Alzheimer's patients. However, this study was terminated early. Clinical pharmacology/efficacy parameters planned in the protocol were not evaluated at the end of the study
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:nuzefatide pevedotin [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04296370: Phase 3 Interventional Recruiting Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01158404: Phase 1 Interventional Completed Advanced Cancer
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
